Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 4
2005 2
2006 4
2007 6
2008 6
2009 2
2010 4
2011 3
2012 4
2013 7
2014 10
2015 13
2016 7
2017 7
2018 8
2019 8
2020 4
2021 6
2022 18
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J. Heuser M, et al. Among authors: maurillo l. Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. Blood. 2021. PMID: 34724563 Free PMC article.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: maurillo l. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
MRD in AML: The Role of New Techniques.
Voso MT, Ottone T, Lavorgna S, Venditti A, Maurillo L, Lo-Coco F, Buccisano F. Voso MT, et al. Among authors: maurillo l. Front Oncol. 2019 Jul 23;9:655. doi: 10.3389/fonc.2019.00655. eCollection 2019. Front Oncol. 2019. PMID: 31396481 Free PMC article. Review.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. Todisco E, et al. Among authors: maurillo l. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24. Cancer. 2023. PMID: 36692409 Free article.
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients.
Catalano G, Zaza A, Banella C, Pelosi E, Castelli G, de Marinis E, Smigliani A, Travaglini S, Ottone T, Divona M, Del Principe MI, Buccisano F, Maurillo L, Ammatuna E, Testa U, Nervi C, Venditti A, Voso MT, Noguera NI. Catalano G, et al. Among authors: maurillo l. Leukemia. 2023 Aug;37(8):1600-1610. doi: 10.1038/s41375-023-01946-5. Epub 2023 Jun 22. Leukemia. 2023. PMID: 37349598
Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.
Palmieri R, Paterno G, Mallegni F, Frenza F, De Bernardis I, Moretti F, Meddi E, Del Principe MI, Maurillo L, Venditti A, Buccisano F. Palmieri R, et al. Among authors: maurillo l. Mediterr J Hematol Infect Dis. 2023 Sep 1;15(1):e2023051. doi: 10.4084/MJHID.2023.051. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37705524 Free PMC article. Review.
Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia.
Palmieri R, Maurillo L, Del Principe MI, Paterno G, Walter RB, Venditti A, Buccisano F. Palmieri R, et al. Among authors: maurillo l. Cancers (Basel). 2022 Dec 26;15(1):136. doi: 10.3390/cancers15010136. Cancers (Basel). 2022. PMID: 36612132 Free PMC article.
Treatment of Low-Blast Count AML using Hypomethylating Agents.
De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT. De Bellis E, et al. Among authors: maurillo l. Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28698788 Free PMC article. Review.
An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI, Paterno G, Palmieri R, Maurillo L, Buccisano F, Venditti A. Del Principe MI, et al. Among authors: maurillo l. Expert Opin Pharmacother. 2019 Nov;20(16):1935-1942. doi: 10.1080/14656566.2019.1654456. Epub 2019 Aug 27. Expert Opin Pharmacother. 2019. PMID: 31454277 Review.
117 results